Dr. Freedland on next steps with cabazitaxel in prostate cancer

Stephen J. Freedland, MD, shares his thoughts on the next steps for cabazitaxel (Jevtana) in the prostate cancer paradigm. Freedland is director of the Center for Integrated Research in Cancer and Lifestyle, co-director of the Cancer Genetics and Prevention Program and associate director for faculty development at the Cancer Institute. He is a faculty physician in the Division of Urology at the Cedars-Sinai Surgery Department.

Freedland is a speaker and consultant for Jevtana developer Sanofi, as well as several other pharmaceutical companies.